連接符號後的空白
2008/01/24 09:30
瀏覽384
迴響0
推薦2
引用0
相隔一日,二位了不起的科學家-福克曼與吳京博士-相繼過世,令人唏噓不已.
福克曼博士最終與諾貝爾獎失之交臂.他生前倡導以抗血管新生療法治療癌症,DNA結構發現者詹姆士華特生稱之為"癌症終極療法",喧騰一時.以後許多研究指出抗血管新生療法有其限制,導致福克曼博士不斷與人筆戰.其中著者為美國國立癌症研究所的派特.史蒂格(Pat Steeg)博士.她的研究顯示抗血管新生療法甚至可能導致腫瘤擴散.據說福克曼曾經對著史蒂格大吼:你毀了我的諾貝爾獎!
福克曼一生不斷努力,嚐試將他發現的二種抗血管新生蛋白用於癌症治療上,卻都沒有太大成果.單一抗血管新生劑在臨床試驗中抗癌效果有限,令他挫折深重.近年來研究指出,腫瘤與周邊組織作用複雜,彼此維護惡性環境,可能須多重療法才能對付.最近臨床研究證明,抗血管新生劑與化療或標靶療法合併使用可增進抗癌效果,又不增副作用.而抗血管新生劑如「癌思停」（ Avastin ）終獲核准上市.福克曼博士眼見諾貝爾獎在望...
他卻在此時填上了括號裡連接符號後的空白. Dr. Moses Judah Folkman (February 24, 1933 - 14 January 2008) .
Judah Folkman
en.wikipedia.org/wiki/Judah_Folkman
Dr. Moses Judah Folkman (February 24, 1933 - 14 January 2008) was an American cellular scientist best known for his research on angiogenesis and vasculogenesis, i.e., he discovered that tumours generate tiny blood vessels to nourish themselves. His work founded a branch of cancer research called 'anti-angiogenesis therapy'.
Born in Cleveland, Ohio, Dr. Folkman graduated Ohio State University in 1953, and then Harvard Medical School[1] in 1957. While still a student at Harvard Medical School, he developed one of the first pacemakers[2]. After his graduation, he worked at Massachusetts General Hospital, where he rose to the rank of chief resident in surgery. During this time, Folkman worked on liver cancer and atrio-pacemakers.
Between 1960 and 1962, Folkman served in the U.S. Navy, as a Lieutenant, where he studied blood vessel growth. He worked at the National Naval Medical Center in Bethesda, Maryland. During his service in the U.S. Navy, Folkman created an implantable device for timed drug-release, and donated it patent-free to the World Population Council. It is now known as Norplant. [3]
In 1971, he published an article in the New England Journal of Medicine, stating that all cancer tumors were angiogenesis-dependent. He postulated that if a tumour could be stopped from grrowing its own blood supply, it would wither and die. Though his hypothesis was disregarded by most experts in the field at first, Folkman continued his research.
After more than a decade, his theory became widely accepted. He was considered the leading expert and founder of the angiogenesis field, which now offers many potentials in medicine. He trained numerous leaders in medicine and biomedical engineering, including Donald Ingber and Robert Langer.
Dr. Folkman pioneered the use of interferon in cancer therapy, healing hemangiomas, growths that often threaten the life of infants. His research has led to the development of progressively more potent compounds, such as angiostatin, endostatin and vasculostatin, which have successfully halted the growth of tumors in laboratory mice[4].
In 2000, a pharmaceutical company has sued Dr. Folkman, contending that he and Children's Hospital in Boston stole the credit for developing a promising drug that cuts off the blood supply to tumors[5][6], and he countersued to defend his preputation[7].
Dr. Folkman died in Denver[8]. At the time of his death, Dr. Folkman was Professor of Cell Biology at Harvard Medical School and was also director of the Vascular Biology Program at Children's Hospital Boston[9].
福克曼博士最終與諾貝爾獎失之交臂.他生前倡導以抗血管新生療法治療癌症,DNA結構發現者詹姆士華特生稱之為"癌症終極療法",喧騰一時.以後許多研究指出抗血管新生療法有其限制,導致福克曼博士不斷與人筆戰.其中著者為美國國立癌症研究所的派特.史蒂格(Pat Steeg)博士.她的研究顯示抗血管新生療法甚至可能導致腫瘤擴散.據說福克曼曾經對著史蒂格大吼:你毀了我的諾貝爾獎!
福克曼一生不斷努力,嚐試將他發現的二種抗血管新生蛋白用於癌症治療上,卻都沒有太大成果.單一抗血管新生劑在臨床試驗中抗癌效果有限,令他挫折深重.近年來研究指出,腫瘤與周邊組織作用複雜,彼此維護惡性環境,可能須多重療法才能對付.最近臨床研究證明,抗血管新生劑與化療或標靶療法合併使用可增進抗癌效果,又不增副作用.而抗血管新生劑如「癌思停」（ Avastin ）終獲核准上市.福克曼博士眼見諾貝爾獎在望...
他卻在此時填上了括號裡連接符號後的空白. Dr. Moses Judah Folkman (February 24, 1933 - 14 January 2008) .
Judah Folkman
en.wikipedia.org/wiki/Judah_Folkman
Dr. Moses Judah Folkman (February 24, 1933 - 14 January 2008) was an American cellular scientist best known for his research on angiogenesis and vasculogenesis, i.e., he discovered that tumours generate tiny blood vessels to nourish themselves. His work founded a branch of cancer research called 'anti-angiogenesis therapy'.
Born in Cleveland, Ohio, Dr. Folkman graduated Ohio State University in 1953, and then Harvard Medical School[1] in 1957. While still a student at Harvard Medical School, he developed one of the first pacemakers[2]. After his graduation, he worked at Massachusetts General Hospital, where he rose to the rank of chief resident in surgery. During this time, Folkman worked on liver cancer and atrio-pacemakers.
Between 1960 and 1962, Folkman served in the U.S. Navy, as a Lieutenant, where he studied blood vessel growth. He worked at the National Naval Medical Center in Bethesda, Maryland. During his service in the U.S. Navy, Folkman created an implantable device for timed drug-release, and donated it patent-free to the World Population Council. It is now known as Norplant. [3]
In 1971, he published an article in the New England Journal of Medicine, stating that all cancer tumors were angiogenesis-dependent. He postulated that if a tumour could be stopped from grrowing its own blood supply, it would wither and die. Though his hypothesis was disregarded by most experts in the field at first, Folkman continued his research.
After more than a decade, his theory became widely accepted. He was considered the leading expert and founder of the angiogenesis field, which now offers many potentials in medicine. He trained numerous leaders in medicine and biomedical engineering, including Donald Ingber and Robert Langer.
Dr. Folkman pioneered the use of interferon in cancer therapy, healing hemangiomas, growths that often threaten the life of infants. His research has led to the development of progressively more potent compounds, such as angiostatin, endostatin and vasculostatin, which have successfully halted the growth of tumors in laboratory mice[4].
In 2000, a pharmaceutical company has sued Dr. Folkman, contending that he and Children's Hospital in Boston stole the credit for developing a promising drug that cuts off the blood supply to tumors[5][6], and he countersued to defend his preputation[7].
Dr. Folkman died in Denver[8]. At the time of his death, Dr. Folkman was Professor of Cell Biology at Harvard Medical School and was also director of the Vascular Biology Program at Children's Hospital Boston[9].
你可能會有興趣的文章：
限會員,要發表迴響,請先登入
